Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Rolling Hills Estates, California Clinical Trials

A listing of Rolling Hills Estates, California clinical trials actively recruiting patient volunteers.

RESULTS

Found (9) clinical trials

Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive HER2-negative Advanced Breast Cancer

The purpose of this study is to assess the efficacy of LEE011, as measured by progression free survival (PFS), in premenopausal women with HR positive, HER2 negative advanced breast cancer

Phase

3.3 miles

Learn More »

A Study Evaluating ABI-H0731+ NUC vs NUC Alone for the Treatment of Viremic HBeAg-positive CHB Patients

This is a Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Patients With Chronic Hepatitis B

Phase

3.41 miles

Learn More »

A Study of JNJ-63723283 a Programmed Cell Death Receptor-1 (PD-1) Inhibitor Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer

This study is of participants with mCRPC who have progressed after therapy with an androgen receptor (AR)-targeted agent and have not received chemotherapy. Participants must have confirmed prostate-specific antigen (PSA) progression per Prostate Cancer Clinical Trials Working Group (PCWG3) criteria. The primary hypothesis is that treatment with JNJ-63723283 and apalutamide ...

Phase

3.41 miles

Learn More »

Study of Topical SOR007 Ointment for Cutaneous Metastases

This is a Phase 1/2, open-label, dose-rising study evaluating the safety, tolerability and preliminary efficacy of three concentrations of SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment (0.15%, 1.0%, and 2.0%) applied to non-melanoma cutaneous metastases. A treatment area of 50 cm2 will be selected by the Investigator. Using a gloved hand, subjects ...

Phase

3.41 miles

Learn More »

A Study Evaluating ABI-H0731 as Adjunctive Therapy in HBeAg-positive Patients With Chronic Hepatitis B

This is a Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731 as Adjunctive Therapy in Virally-suppressed HBeAg-positive Patients with Chronic Hepatitis B

Phase

3.41 miles

Learn More »

A Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) in Combination With Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

This is a randomized (individuals assigned to study treatment by chance), double-blind (individuals and study personnel will not know the identity of study treatments), placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial)-controlled study to compare ...

Phase

3.41 miles

Learn More »

Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

This is an open labeled, multi-center, phase I/II, cohort study involving a single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) lentiviral vector G2SCID in up to 10 patients with X-linked SCID (SCID-X1) at Boston Children's Hospital and UCLA Mattel Children's Hospital. Patients will receive transduced cells after ...

Phase

3.41 miles

Learn More »

EndoTAG-1 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment

The aim of this adaptive Phase 3 trial is to show a statistically significant superiority of EndoTAG-1 in combination with gemcitabine compared to gemcitabine monotherapy in patients with locally advanced/metastatic pancreatic cancer after FOLFIRINOX failure.

Phase

3.41 miles

Learn More »

Safety Tolerability PK Profile and Symptom Response of a 7-Day Dosing With 25 mg Daily and 50 mg Daily of REL-1017 in Major Depressive Disorder

Currently available medications have proven to be useful for the treatment of depression, but also have limitations including low response rates, a significant number of treatment resistant patients, and time-lag for response, which emphasizes a major unmet need for more efficacious and faster-acting antidepressants. Recent studies have demonstrated that ketamine, ...

Phase

9.86 miles

Learn More »